Effects of somatostatin and bromocryptine on the plasma ACTH level in bilaterally adrenalectomized patients with Cushing's disease

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)

Abstract

The effects of somatostatin and bromocryptine were examined in patients bilaterally adrenalectomized because of Cushing's disease, in one of whom Nelson's syndrome had developed. Following a 250 μg (152 nmol) somatostatin bolus, administered i.v., a further 250 μg (152 nmol) somatostatin was given by infusion over 90 minutes. In all patients the high basal value of the serum ACTH was considerably decreased 60 minutes after the bolus, but after 240 minutes the basic value was almost restored. In the patients without Nelson's syndrome the plasma ACTH decreasing action of oral 2.5 mg (3.38 μmol) bromocryptine exceeded 300 minutes. In the Nelson's syndrome patient the early ACTH-decreasing effect of bromocryptine was greater, but after 300 minutes the ACTH level had risen to nearly twice the basic value.

Original languageEnglish
Title of host publicationEndokrinologie
Pages68-72
Number of pages5
Volume76
Edition1
Publication statusPublished - 1980

Fingerprint

Pituitary ACTH Hypersecretion
Nelson Syndrome
Bromocriptine
Somatostatin
Adrenocorticotropic Hormone
Serum

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of somatostatin and bromocryptine on the plasma ACTH level in bilaterally adrenalectomized patients with Cushing's disease. / Julesz, J.; Laczi, F.; Janáky, T.; László, F.

Endokrinologie. Vol. 76 1. ed. 1980. p. 68-72.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{246cf75ad739481ea7027c24d7831a2a,
title = "Effects of somatostatin and bromocryptine on the plasma ACTH level in bilaterally adrenalectomized patients with Cushing's disease",
abstract = "The effects of somatostatin and bromocryptine were examined in patients bilaterally adrenalectomized because of Cushing's disease, in one of whom Nelson's syndrome had developed. Following a 250 μg (152 nmol) somatostatin bolus, administered i.v., a further 250 μg (152 nmol) somatostatin was given by infusion over 90 minutes. In all patients the high basal value of the serum ACTH was considerably decreased 60 minutes after the bolus, but after 240 minutes the basic value was almost restored. In the patients without Nelson's syndrome the plasma ACTH decreasing action of oral 2.5 mg (3.38 μmol) bromocryptine exceeded 300 minutes. In the Nelson's syndrome patient the early ACTH-decreasing effect of bromocryptine was greater, but after 300 minutes the ACTH level had risen to nearly twice the basic value.",
author = "J. Julesz and F. Laczi and T. Jan{\'a}ky and F. L{\'a}szl{\'o}",
year = "1980",
language = "English",
volume = "76",
pages = "68--72",
booktitle = "Endokrinologie",
edition = "1",

}

TY - CHAP

T1 - Effects of somatostatin and bromocryptine on the plasma ACTH level in bilaterally adrenalectomized patients with Cushing's disease

AU - Julesz, J.

AU - Laczi, F.

AU - Janáky, T.

AU - László, F.

PY - 1980

Y1 - 1980

N2 - The effects of somatostatin and bromocryptine were examined in patients bilaterally adrenalectomized because of Cushing's disease, in one of whom Nelson's syndrome had developed. Following a 250 μg (152 nmol) somatostatin bolus, administered i.v., a further 250 μg (152 nmol) somatostatin was given by infusion over 90 minutes. In all patients the high basal value of the serum ACTH was considerably decreased 60 minutes after the bolus, but after 240 minutes the basic value was almost restored. In the patients without Nelson's syndrome the plasma ACTH decreasing action of oral 2.5 mg (3.38 μmol) bromocryptine exceeded 300 minutes. In the Nelson's syndrome patient the early ACTH-decreasing effect of bromocryptine was greater, but after 300 minutes the ACTH level had risen to nearly twice the basic value.

AB - The effects of somatostatin and bromocryptine were examined in patients bilaterally adrenalectomized because of Cushing's disease, in one of whom Nelson's syndrome had developed. Following a 250 μg (152 nmol) somatostatin bolus, administered i.v., a further 250 μg (152 nmol) somatostatin was given by infusion over 90 minutes. In all patients the high basal value of the serum ACTH was considerably decreased 60 minutes after the bolus, but after 240 minutes the basic value was almost restored. In the patients without Nelson's syndrome the plasma ACTH decreasing action of oral 2.5 mg (3.38 μmol) bromocryptine exceeded 300 minutes. In the Nelson's syndrome patient the early ACTH-decreasing effect of bromocryptine was greater, but after 300 minutes the ACTH level had risen to nearly twice the basic value.

UR - http://www.scopus.com/inward/record.url?scp=0019202526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019202526&partnerID=8YFLogxK

M3 - Chapter

C2 - 6108208

AN - SCOPUS:0019202526

VL - 76

SP - 68

EP - 72

BT - Endokrinologie

ER -